SCHEMBL2298056

SCHEMBL2298056

Oc1cc(-c2nc(NCc3ccccc3)c3ccccc3n2)cc(O)c1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.72
KMT2A Q03164 11/20 0.72
PDE5A O76074 6/20 0.72
GBA1 P04062 2/20 0.72
ATM Q13315 1/20 0.72
RXFP1 Q9HBX9 1/20 0.68
PTGS1 P23219 2/20 0.66
TBXAS1 P24557 2/20 0.66
PTGS2 P35354 2/20 0.66
LMNA P02545 7/20 0.62
MAPT P10636 3/20 0.62
CYP1A2 P05177 8/20 0.62
CYP3A4 P08684 8/20 0.62
CYP2D6 P10635 8/20 0.62
CYP2C19 P33261 8/20 0.62
ALDH1A1 P00352 8/20 0.62
HSD17B10 Q99714 6/20 0.62
MAPK1 P28482 6/20 0.62
USP2 O75604 5/20 0.62
CLK4 Q9HAZ1 5/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303236 0.92 MEN1 (0.61) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2291454 0.89 LMNA (0.66) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2294872 0.88 MEN1 (0.61) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2297695 0.87 USP1 (0.61) MEN1KMT2APDE5AGBA1ATM
SCHEMBL1083763 0.84 PDE5A (1.00) MEN1KMT2APDE5AGBA1ATM
SCHEMBL1084041 0.81 KMT2A (1.00) MEN1KMT2APDE5AGBA1ATM
SCHEMBL7277479 0.80 PDE5A (1.00) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2296338 0.80 ABCG2 (0.70) MEN1KMT2APDE5AGBA1LMNA
SCHEMBL1084183 0.80 MEN1 (0.89) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2583256 0.78 PDE5A (0.90) MEN1KMT2APDE5AGBA1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528606-B1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS LEVITZKI ALEXANDER (IL) 2014-09-24 EP disclosed
US-8759363-B2 Quinazoline-based T cell proliferation inhibitors YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-06-24 US disclosed
US-20130109706-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSALEM LTD. (IL) 2013-05-02 US disclosed
EP-2528606-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2012-12-05 EP disclosed
WO-2011092695-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109706-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS IL2, CD4, NFATC1 MEN1 3730/4885KMT2A 1486/4885PDE5A 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.